RHUMBLINE ADVISERS

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 1115418 BOSTON, MA

Position in TSHA

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$1,155,629

-$260,291 QoQ

Shares Held

258,530

+0.4% QoQ

Ownership

0.090%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2021

12 quarters on record

Voting authority Sole 21.38978068309287.ToString("F0")% Shared 0.ToString("F0")% None 78.61021931690712.ToString("F0")%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. TSHA ranks #110 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,155,629	258,530	+0.4%	Shares	Sole	2026-05-12
2025-12-31	$1,415,920	257,440	-10.9%	Shares	Sole	2026-02-13
2025-09-30	$944,568	288,859	+23.8%	Shares	Sole	2025-11-06
2025-06-30	$538,821	233,256	+13.5%	Shares	Sole	2025-08-12
2025-03-31	$285,592	205,462	+7.0%	Shares	Sole	2025-05-29
2024-12-31	$332,296	192,079	+3.1%	Shares	Sole	2025-05-29
2024-09-30	$374,358	186,248	+1.1%	Shares	Sole	2024-11-12
2024-06-30	$412,796	184,284	+723.1%	Shares	Sole	2024-08-01
2022-03-31	$145,976	22,389	+13.2%	Shares	Sole	2022-05-12
2021-12-31	$230,320	19,770	-1.8%	Shares	Sole	2022-02-10
2021-09-30	$374,839	20,131	+7.8%	Shares	Sole	2021-11-12
2021-06-30	$395,825	18,671	—	Shares	Sole	2021-08-05
No filing history on record for this holder in this stock.